Teva Eyes 2027 Growth Despite Austedo Price Caps
Teva Pharmaceutical Industries anticipates continued growth in 2027 even as the US inflation reduction act caps prices for its top drug Austedo. CEO Richard Francis notes strong branded drugs and a growing biosimilars pipeline will offset generics weakness.
Insights:
Teva Pharmaceutical Industries expects revenue growth in 2027 despite U.S. price caps on its top branded drug, CEO Richard Francis said on Tuesday afternoon. The forecast comes as pharmaceutical companies navigate new pricing pressures in the United States. For investors, the resilience in core segments signals stable cash flows ahead of major drug launches.
